Teva Pharmaceutical Industries LTD 8-K filings

Teva Pharmaceutical Industries Ltd. announced robust second-quarter 2026 financial results, driven by significant growth in its key innovative brands, leading to an upward revision of its full-year outlook.

Teva Pharmaceutical Industries Limited shareholders approved the election of Dr. Sol J. Barer to the Board and ratified executive compensation and auditor appointments.

Teva Pharmaceutical Industries Ltd. announced robust first-quarter 2026 financial results driven by its innovative portfolio and disciplined execution, alongside a definitive agreement to acquire Emalex Biosciences for its neuroscience pipeline.

Teva Pharmaceutical Industries Ltd. announced its 2025 financial results, marking a third consecutive year of growth driven by its innovative brands and strategic execution.

Teva Pharmaceutical Industries Ltd. presented its 'Pivot to Growth' strategy, 2025 financial expectations, and long-term targets through 2030 at the J.P. Morgan Healthcare Conference.

Teva Pharmaceutical Industries Limited secured an extension of its revolving credit facility maturity date to April 2028 and amended financial covenants, including a suspension clause for investment-grade status.

Teva Pharmaceutical Industries reports strong Q3 2025 results, driven by innovative brands and an increased outlook for Austedo, despite some segment declines.

Teva Pharmaceutical Industries Ltd. reported its tenth consecutive quarter of year-over-year revenue growth in Q2 2025, fueled by its innovative product portfolio, leading to an increased 2025 revenue outlook for key innovative products and EPS.

Teva Pharmaceutical Industries Ltd. announced that its shareholders approved all proposals at the Annual Meeting on June 5, 2025, including the election of directors and various compensation-related amendments.

Teva Pharmaceutical Industries Ltd.'s subsidiaries have successfully issued a total of $1.2 billion in U.S. Dollar-denominated senior notes and €1 billion in Euro-denominated senior notes, with proceeds primarily allocated to an upsized tender offer for existing debt and general debt repayment.

Teva Pharmaceutical Industries Ltd. successfully increased its senior notes offering to $2.3 billion (equivalent) to repay existing debt and fund tender offers.

Teva Pharmaceutical Industries Ltd. reports a strong Q1 2025 with revenue growth and an improved profit outlook, driven by key innovative medicines.

Teva Pharmaceutical Industries Ltd. announced a second consecutive year of growth in 2024, with revenues reaching $16.5 billion, driven by strong performance in generics and key innovative products.

Teva Pharmaceutical Industries Ltd. has appointed Chen Lichtenstein, a former CFO of Syngenta Group, to its Board of Directors, effective December 1, 2024.

Teva Pharmaceutical Industries Ltd. announced strong third-quarter 2024 financial results, driven by generics performance and innovative portfolio growth, leading to an increased full-year outlook.

Teva Pharmaceutical Industries Ltd. announced a 7% revenue increase in Q2 2024, driven by generics and AUSTEDO, leading to raised financial guidance for the year.

Teva Pharmaceutical Industries has reached an agreement with the Israeli Tax Authorities to settle tax litigation for $750 million, payable over several years.

Teva Pharmaceutical Industries held its annual meeting on June 6, 2024, where shareholders elected directors, approved executive compensation on an advisory basis, and appointed an independent auditor.

Teva Pharmaceutical Industries Ltd. has appointed Matthew Shields as Executive Vice President of Global Operations, effective June 3, 2024, succeeding Eric Drap.

Teva's first quarter of 2024 saw a 5% revenue increase in local currency, fueled by generics and key product growth, with reaffirmed financial outlook for the year.

Teva Pharmaceutical Industries Limited has announced a change in its reporting segments, moving Canada from the North America segment to the International Markets segment, effective January 1, 2024, and has provided recast historical financial data to reflect this change.

Teva Pharmaceutical Industries Ltd. announced a 7% revenue increase in local currency for 2023, driven by growth in key innovative brands and strategic collaborations.